Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classificationEnrico Caliman(University of Florence), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi)Lung CancerNovember 24, 202210.1016/j.lungcan.2022.11.014Cited by 47SaveCiteExport RISWatch citationsRelated PapersUpfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial|The Lancet Oncology|2020|322Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial|The Lancet Oncology|2022|268Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours|Journal of Hepatology|2023|62